Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases.
Perella Weinberg Partners is an independent, privately-owned financial services firm that provides corporate advisory and asset management services to clients around the world. The Firm has assembled a group of talented and experienced professionals recruited from a wide variety of leading global financial institutions.
Launched in 2006, the company is divided into two business units: corporate advisory, which provides services to decision makers in business and government, and asset management, which consists of investment vehicles catering to institutional investors.
Lendbuzz Funding, LLC offers car loans to expats and international students. The company does not require Social Security Number (SSN) and provides loans to all visa holders from all nationalities. Its customers include students, international professionals, and other young professionals that have an international credit file. The company provides access and manages its loans through an online platform and data-intensive scoring technology. Lendbuzz Funding, LLC was founded in 2015 and is based in Boston, Massachusetts.
Latch makes access easier for everyone at a modern building. The company specializes in manufacturing keyless entry security system giving property owners the ability to manage every door in a multi-family building. Moreover, residents can also give access to guests as well as service providers through time-limited access codes. Latch is headquartered in New York, New York, United States.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. It was founded in 2017 and is based in Cambridge, Massachusetts.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Greenlight Financial Technology, Inc. is a financial services company that offers debit card solutions designed specifically for children, enabling parents to instill financial literacy from an early age. Founded in 2014 and headquartered in Atlanta, Georgia, Greenlight provides a mobile application that allows parents to manage their children’s spending by designating specific stores where the Greenlight debit card can be used. This patent-pending technology empowers families to create teachable moments around earning, saving, spending, and giving. By focusing on convenience and safety, Greenlight aims to help parents raise financially savvy children while also expanding its network across the United States.
Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.
Cityblock Health is a healthcare provider focused on delivering primary care, behavioral health, and virtual care services to lower-income communities. Established in 2017 and based in Brooklyn, New York, Cityblock leverages technology to offer personalized, prevention-oriented care for urban residents with complex health needs. The company's platform facilitates access to preventive visits, mental health services, and social support programs. Additionally, Cityblock offers a communication tool called Commons, which enhances information sharing and task management among members and care teams. During the COVID-19 pandemic, Cityblock developed a model to identify individuals at high risk, highlighting its commitment to addressing urgent health challenges. By prioritizing upstream investments in health and social care, Cityblock aims to improve health outcomes while reducing overall costs.
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.
Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.
Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing advanced precision oncology therapies for cancer treatment. Founded in 2020, the company aims to enhance the accessibility and effectiveness of precision medicine for cancer patients. Scorpion Therapeutics specializes in creating drugs in three primary areas: therapies targeting known oncogenes, agents for currently undruggable cancer targets, and innovative drugs for new targets. By integrating state-of-the-art technologies in target discovery, medicinal chemistry, and translational medicine, the company is committed to delivering next-generation precision oncology solutions. Its experienced leadership team is dedicated to employing a tailored approach to efficiently advance the field of precision cancer treatment.
Cityblock Health is a healthcare provider focused on delivering primary care, behavioral health, and virtual care services to lower-income communities. Established in 2017 and based in Brooklyn, New York, Cityblock leverages technology to offer personalized, prevention-oriented care for urban residents with complex health needs. The company's platform facilitates access to preventive visits, mental health services, and social support programs. Additionally, Cityblock offers a communication tool called Commons, which enhances information sharing and task management among members and care teams. During the COVID-19 pandemic, Cityblock developed a model to identify individuals at high risk, highlighting its commitment to addressing urgent health challenges. By prioritizing upstream investments in health and social care, Cityblock aims to improve health outcomes while reducing overall costs.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
Attentive Mobile, Inc. is a personalized mobile messaging platform that enables companies to effectively acquire, retain, and engage with their mobile audiences. Founded in 2016 and headquartered in New York, the company serves a diverse range of industries, including e-commerce, retail, food and beverage, travel, hospitality, entertainment, media, publishing, education, and non-profit sectors. By leveraging real-time behavioral data, Attentive automates the delivery of tailored text messages throughout the customer lifecycle, which includes product recommendations, special promotions, payment notifications, and real-time customer service. With over 2,000 clients, including well-known brands like Sephora and Urban Outfitters, Attentive has demonstrated significant effectiveness, achieving impressive metrics such as over 30% click-through rates and more than 25 times return on investment.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Prove provides a phone-centric identity platform designed to enhance security and reduce fraud through the use of phone numbers. With over 1 billion identity tokens under management, Prove assists more than 1,000 companies and over 500 banks, including leading financial institutions, in securing their customer onboarding, digital services, and payment processes. The company offers two primary solutions: Prove Pre-fill™, which streamlines the onboarding process by authenticating consumer identities and auto-filling verified data, and Fonebook™, which provides a comprehensive identity authentication platform to manage customer phone numbers and create a unified customer view across various channels. Additionally, Prove offers multi-factor authentication options, including SMS and voice OTPs, instant link authentication, mobile authentication through cellular networks, voice biometrics, and app-based push authentication. These features enable secure transactions and enhance the overall customer experience across mobile, desktop, and in-store environments. Prove's services are available in 195 countries, underscoring its global reach in identity verification and fraud mitigation.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
ACV Auctions, Inc. is a wholesale automotive auction company that operates a mobile platform designed for used-car dealers. Founded in 2014 and headquartered in Buffalo, New York, ACV enables dealers to view, bid on, and purchase car inventory through online auctions. The platform facilitates dealer-to-dealer transactions by allowing users to select desired vehicles and receive alerts on their mobile devices when specific cars become available. Additionally, ACV provides a pricing application for franchise dealers and acts as a closing tool for wholesale buyers to bid on vehicles. This innovative marketplace streamlines the buying and selling process within the automotive industry.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Away is a modern travel and lifestyle brand. The company is a vertically-integrated company offering beautiful, high-quality luggage at an affordable price point. Away designs special objects for modern travel. It started with luggage, designed with thoughtful features that solve real travel problems—for life. Now all that’s left is the world in front of you and the people you share it with. Because getting Away means getting more out of every trip to come.
Prove provides a phone-centric identity platform designed to enhance security and reduce fraud through the use of phone numbers. With over 1 billion identity tokens under management, Prove assists more than 1,000 companies and over 500 banks, including leading financial institutions, in securing their customer onboarding, digital services, and payment processes. The company offers two primary solutions: Prove Pre-fill™, which streamlines the onboarding process by authenticating consumer identities and auto-filling verified data, and Fonebook™, which provides a comprehensive identity authentication platform to manage customer phone numbers and create a unified customer view across various channels. Additionally, Prove offers multi-factor authentication options, including SMS and voice OTPs, instant link authentication, mobile authentication through cellular networks, voice biometrics, and app-based push authentication. These features enable secure transactions and enhance the overall customer experience across mobile, desktop, and in-store environments. Prove's services are available in 195 countries, underscoring its global reach in identity verification and fraud mitigation.
ezCater, Inc. provides online catering ordering solutions for small start-ups and Fortune 500 companies. Its solutions enable users to order food online for meetings. The company offers ezManage, a catering management platform; and ezOrdering that provides restaurants with means to accept online catering orders on their own website. ezCater, Inc. was founded in 2007 and is based in Boston, Massachusetts. It has an additional office in Denver, Colorado.
ezCater, Inc. provides online catering ordering solutions for small start-ups and Fortune 500 companies. Its solutions enable users to order food online for meetings. The company offers ezManage, a catering management platform; and ezOrdering that provides restaurants with means to accept online catering orders on their own website. ezCater, Inc. was founded in 2007 and is based in Boston, Massachusetts. It has an additional office in Denver, Colorado.
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Compass is a real estate brokerage company based in New York City, founded in 2012 by Ori Allon, Robert Reffkin, and Ugo Di Girolamo. The company offers a comprehensive platform for residential real estate agents, equipping them with a suite of cloud-based software tailored for customer relationship management, marketing, and client service. This integrated approach enhances the ability of agents to provide exceptional service to buyers and sellers. In addition to its brokerage services, Compass has developed a mobile app for iOS and Android that facilitates buying, selling, and renting homes across the United States. The company operates primarily within the domestic market.
WeWork, known as The We Company, is a commercial real estate firm that specializes in providing flexible workspaces and office services primarily for entrepreneurs and technology startups. Founded in 2010 and headquartered in New York, the company transforms buildings into dynamic environments that foster creativity, collaboration, and productivity. Its offerings include a variety of workplace solutions such as private offices, shared workspaces, and on-demand access to workstations, catering to diverse member needs. In addition to physical spaces, WeWork provides a range of services through partnerships, enabling members to work, live, and grow. The company also operates WeWork Labs, which supports early-stage startups by providing community and programming to aid their development. With a focus on inclusivity and community, WeWork aims to create an environment where members can thrive and innovate together.
Vets First Choice provides veterinary practices with an online pharmacy and home delivery services. It partners with veterinarians to create insight into gaps in patient care and offer professionalized pro-active prescription management to drive client engagement and improve compliance. The company was founded by Ben Shaw in 2010 and is based in Portland, Maine.
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Defy Media, Inc. specializes in creating and distributing digital content targeted at millennials, particularly in the realms of comedy, entertainment, gaming, and lifestyle. Formed from the merger of Alloy Digital and Break Media, the company has established itself as a significant player in the digital media landscape, producing influential programming for consumers aged 13 to 34. With a strong portfolio of popular brands and effective production, distribution, and marketing capabilities, Defy Media engages its audience across over 25 video platforms, including subscription video on demand (SVOD), television, and film. Incorporated in 2011 and based in New York, Defy Media was previously known as Alloy Digital before rebranding in 2013. It operates as a subsidiary of Alloy, Inc.
Compass is a real estate brokerage company based in New York City, founded in 2012 by Ori Allon, Robert Reffkin, and Ugo Di Girolamo. The company offers a comprehensive platform for residential real estate agents, equipping them with a suite of cloud-based software tailored for customer relationship management, marketing, and client service. This integrated approach enhances the ability of agents to provide exceptional service to buyers and sellers. In addition to its brokerage services, Compass has developed a mobile app for iOS and Android that facilitates buying, selling, and renting homes across the United States. The company operates primarily within the domestic market.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
General Assembly provides education and career transformation, specializing in today’s most in-demand skills. The leading source for training, staffing, and career transitions, we foster a flourishing community of professionals pursuing careers they love.
It was founded in 2011 and headquartered in New York, United States.
Rhythm Metabolic
Series A in 2015
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
Harry's, Inc. is a company that specializes in the manufacture and sale of shaving products. Founded in 2012 and headquartered in New York, the company designs and produces its own line of razors, replacement blades, shaving creams, grooming kits, and face care products. Harry's operates primarily through an online platform, offering its products individually or through a subscription model, catering to men's grooming needs. By focusing on quality and convenience, Harry's aims to simplify the shaving experience for consumers.
Warby Parker is a lifestyle brand specializing in the design and sale of vintage-inspired eyeglasses and sunglasses, including prescription glasses and contact lenses. The company aims to provide affordable eyewear while addressing the global issue of vision impairment, as approximately one billion people lack access to affordable glasses. By partnering with experienced non-profit organizations, Warby Parker ensures that each pair of glasses sold helps someone in need obtain eyewear, contributing to improved quality of life and economic opportunities. The company operates through various channels, including physical stores, its website, and mobile applications, offering a range of optical services such as eye exams and vision tests. Revenue is primarily generated from the sale of eyewear products, accessories, and related services.
Jounce Therapeutics is a clinical-stage immunotherapy company focused on developing innovative cancer treatments that harness the immune system to target and eliminate cancer cells. The company's lead product, vopratelimab, is a monoclonal antibody currently in Phase II trials for patients with non-small cell lung cancer and urothelial cancer, particularly those who have not responded to PD-1/PD-L1 inhibitors. Additionally, Jounce is advancing several other therapeutic candidates, including JTX-4014, an anti-PD-1 antibody intended for combination therapy, and JTX-1811, which aims to selectively deplete T regulatory cells in the tumor microenvironment. The company also develops JTX-8064, an antibody targeting a receptor on macrophages. Founded in 2013 by experts in immunobiology and cancer research, Jounce Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to improving patient outcomes through its proprietary immunotherapy platform.
Rethink Robotics is a company based in Boston, Massachusetts, focused on developing advanced robotic solutions for the manufacturing industry. Its flagship product, the Baxter robot, utilizes the Intera software platform to enhance workforce efficiency by integrating trainable, safe, and cost-effective robots alongside skilled human labor. Baxter is designed to automate repetitive and hazardous tasks, such as loading, packing, and inspection, thereby increasing flexibility and reducing operational costs for manufacturers in sectors like automotive, electronics, and consumer goods. Additionally, Rethink Robotics offers the Baxter Research Robot for academic and corporate research, featuring integrated sensors and an open software development kit for custom application development. The company's mission is to drive innovation in robotics and support manufacturers in adapting to the demands of an agile economy. Rethink Robotics is backed by prominent investors, including Bezos Expeditions and Charles River Ventures.
Sharecare is the digital health company that helps people manage all their health in one place. The Sharecare platform provides each person – no matter where they are in their health journey – with a comprehensive and personalized health profile, where they can dynamically and easily connect to the information, evidence-based programs and health professionals they need to live their healthiest, happiest and most productive life. With award-winning and innovative frictionless technologies, scientifically validated clinical protocols and best-in-class coaching tools, Sharecare helps providers, employers and health plans effectively scale outcomes-based health and wellness solutions across their entire populations. To learn more, visit www.sharecare.com.
In 2017 alone, Sharecare has raised more than $100 million in new funding; and more than $300 million in total capital since its founding in 2010. May 26, 2017 Sharecare announced it has received an investment from global alternative investment firm, Summit Partners. Sharecare will use the debt capital to fund new capabilities and acquire talent to support the aggressive growth trajectory of both the company and its platform, where people can manage all their health in one place.
Nanigans is a Boston-based company that offers advertising automation software designed for in-house performance marketing teams. Its Software-as-a-Service platform includes features such as programmatic media buying, predictive revenue optimization, and real-time business intelligence. The software enables businesses to identify and remarket to their most valuable customers across various social and mobile channels. In addition to its headquarters in Boston, Nanigans has offices in New York, San Francisco, Seattle, London, Sydney, and Singapore, reflecting its global presence in the advertising technology sector.
Dataminr, Inc. is a real-time information discovery service that specializes in transforming publicly available data into actionable insights for its clients. Founded in 2009 and based in New York, the company employs an AI platform to detect early signs of high-impact events and emerging risks from a diverse array of sources, including social media, blogs, and the dark web. Its flagship product, Dataminr, provides tailored alerts for various sectors, including finance, news, security, and crisis management. For instance, Dataminr for News enables journalists to receive personalized signals based on specific topics and regions, while Dataminr for Finance offers relevant content streams for financial professionals. The platform is adept at identifying critical information related to incidents, threats, and disruptions, empowering businesses to respond promptly to evolving situations such as terrorist threats, social unrest, and extreme weather events. Through its innovative solutions, Dataminr ensures that clients have the necessary information to act confidently in a rapidly changing environment.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
GreenSky, Inc., a technology company, provides point-of-sale financing and payment solutions to merchants, consumers, and banks. It offers a proprietary technology infrastructure that supports the full transaction lifecycle, including credit application, underwriting, real-time allocation to bank partners, document distribution, funding, settlement, and servicing functions. The company was founded in 2006 and is headquartered in Atlanta, Georgia.
WeWork, known as The We Company, is a commercial real estate firm that specializes in providing flexible workspaces and office services primarily for entrepreneurs and technology startups. Founded in 2010 and headquartered in New York, the company transforms buildings into dynamic environments that foster creativity, collaboration, and productivity. Its offerings include a variety of workplace solutions such as private offices, shared workspaces, and on-demand access to workstations, catering to diverse member needs. In addition to physical spaces, WeWork provides a range of services through partnerships, enabling members to work, live, and grow. The company also operates WeWork Labs, which supports early-stage startups by providing community and programming to aid their development. With a focus on inclusivity and community, WeWork aims to create an environment where members can thrive and innovate together.